Ginkgo Bioworks Forum: Community User: NILUIS

Bei mir ist Elon eingestiegen 🥰

👍

Baillie Gifford ist heute eingestiegen.. gutes Zeichen

Schöner Anstieg die letzten tage. Hoffe das die Gewinne halten.. es wäre noch besser, wenn gute news komme und den Anstieg untermauern.

Raymond James Initiates Coverage On Ginkgo Bioworks Holdings with Outperform Rating, Announces Price Target of $14.5 https://www.streetinsider.com/New+Coverage/Raymond+James+Starts+Ginkgo+Bioworks+Holdings+Inc+%28DNA%29+at+Outperform/19054270.html?classic=1

Eine gewisse Reaktion gab es ja: https://pub.webullfintech.com/us/news-html/b7cd6e8ee65245aaba4b573bea40b0f0.html?theme=2&color=2&hl=en&android_sdk_int=30&canary-version=&_v=1&sp=1&tickerId=950183699&disSymbol=DNA Gingko Bioworks CEO Responds To Short Seller Reports, Says Claim Co. Platform Is A Place For New Startups To Secure Capital, Launch Quickly Is Not A Problem ...

Was könnte der grund sein warum Ginkgo sich nicht zu den vorwürfen von scorpian äußert? Es wäre ja ein leichtes diese zu widerlegen, wenn sie nicht wahr sind

Ginkgo Bioworks rebounds as William Blair becomes bullish despite recent selloff https://seekingalpha.com/news/3752024-ginkgo-bioworks-rebounds-as-william-blair-becomes-bullish-despite-recent-selloff Ginkgo Bioworks (DNA +10.1%) has shed more than 20% after short seller Scorpion Capital called it “a colossal scam” in a report released on Wednesday. However, that has not discouraged William Blair to initiate its coverage with an outperform recommendation as the analyst Matthew Larew sees an opportunity in the platform-based company. “We expect Ginkgo to capture considerable value by democratizing cell programming,” Larew wrote, adding that the company’s platform makes synthetic biology more accessible for companies. Ginkgo Bioworks’ cell programming platform is designed to provide biotechnology applications addressing the needs of a wide range of markets from food and agriculture to industrial chemicals to pharmaceuticals. After the initial selloff on the short report, Ginkgo Bioworks shares recovered on Thursday after ARK Invest — run by notable fund manager Cathie Wood — doubled down on its position in the company. However, two consecutive sessions of declines followed. 

https://www.finanzen.net/nachricht/aktien/nach-tesla-verkaeufen-shortseller-druecken-aktienkurs-cathie-woods-ark-schlaegt-bei-biotech-aktie-zu-10606291

Nochmal auf deutsch....

Ich werde so 🤑 dann heirate ich Cathy

Short attack and Cathy Wood bought some cheap shares. She / Ark invest believes in Ginkgo.

Short report von scorpion capital "1 We are short $DNA. Ginkgo Bioworks is a colossal scam, a Frankenstein mash-up of the worst frauds of the last 20 years. At $23B market cap, it is rare to see a related-party scheme on Ginkgo’s scale in the US markets – it is, quite simply, the US version of the “China Hustle.”" "2 Ginkgo’s business model is based on a dubious shell game. Most of its foundry revenue, an absurd 72% in 2020, and ~100% of its deferred revenue are derived from related-party “customers.” Investments into these entities by Ginkgo and its investors are round-tripped back."

Eine unauffällige deutsche AG, die ein tolles Potenzial hat, ist BRAIN Biotech AG. Die machen so was auch, und mehr.

Newbie28 Im Bereich der synthetischen Biologie gibt es viele Player. Die Hauptexpertise von Ginkgo sehe ich in der effizienten Methode der Genmanipulation der Mikroorganismen, sog. "cell factories". Wir hatten Ginkgo als eines der Startup-Unternehmen im einem Schulprojekt (Bio LK). vor zwei Jahren gab es noch eine Reihe anderer Startups die in diesem Feld aktiv sind. Ob die noch aktiv sind, weiß ich nicht.